Mackenzie Financial’s Trillium Therapeutics Inc. TRIL Stock Holding History

Mackenzie Financial’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,420	Closed	-$376K	–	1538
2021 Q3	$376K	Sell	21,420 -8,862	-29%	-$104K	﹤0.01%	1053
2021 Q2	$293K	Buy	30,282 +8,870	+41%	+$83.5K	﹤0.01%	1071
2021 Q1	$229K	Buy	+21,412	New	+$265K	﹤0.01%	1060
2020 Q4	–	Sell	-10,114	Closed	-$144K	–	1110
2020 Q3	$144K	Buy	+10,114	New	+$101K	﹤0.01%	943

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Mackenzie Financial's TRIL Position: Q4 2021 in Review

Mackenzie Financial sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 21,420 shares — an estimated $376K sold.

Mackenzie Financial first reported a position in TRIL in Q3 2020 and held it in 4 quarters. The position peaked at $376K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Mackenzie Financial reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Mackenzie Financial sold 21,420 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $376K.
Mackenzie Financial first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 4 quarters.
Mackenzie Financial's Trillium Therapeutics Inc. position peaked at $376K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Mackenzie Financial's 13F filing for Q4 2021, filed 14 Feb 2022.